BRPI0418095A - inibidores de quinases dependentes de ciclina, composições e usos relacionados aos mesmos - Google Patents

inibidores de quinases dependentes de ciclina, composições e usos relacionados aos mesmos

Info

Publication number
BRPI0418095A
BRPI0418095A BRPI0418095-0A BRPI0418095A BRPI0418095A BR PI0418095 A BRPI0418095 A BR PI0418095A BR PI0418095 A BRPI0418095 A BR PI0418095A BR PI0418095 A BRPI0418095 A BR PI0418095A
Authority
BR
Brazil
Prior art keywords
dependent kinase
cyclin
kinase inhibitors
compositions
uses related
Prior art date
Application number
BRPI0418095-0A
Other languages
English (en)
Inventor
Nicholas Bockovich
Arthur F Kluge
Chris Oalmann
Krishna K Murthi
Siya Ram
Zhongguo Wang
Jianxing Huang
Original Assignee
Gpc Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gpc Biotech Inc filed Critical Gpc Biotech Inc
Publication of BRPI0418095A publication Critical patent/BRPI0418095A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

"INIBIDORES DE QUINASES DEPENDENTES DE CICLINA, COMPOSIçõES E USOS RELACIONADOS AOS MESMOS". A invenção pertence aos novos inibidores de quinases dependentes de ciclina (cdks) de formula (I) em que os substituintes são como definidos nas reivindicações e especificamente, mas não exclusivamente, como inibidores de cdk/complexos de ciclina. Como descrito aqui, os inibidores desta invenção são capazes de inibir a maquinaria do ciclo celular, e, consequentemente, podem ser úteis na modulação da progressão do ciclo celular. Tais compostos seriam úteis para o tratamento de pacientes tendo os distúrbios associados à proliferação celular excessiva.
BRPI0418095-0A 2003-12-23 2004-12-21 inibidores de quinases dependentes de ciclina, composições e usos relacionados aos mesmos BRPI0418095A (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US53187203P 2003-12-23 2003-12-23
US56013804P 2004-04-06 2004-04-06
US61648004P 2004-10-06 2004-10-06
PCT/US2004/043492 WO2005063765A1 (en) 2003-12-23 2004-12-21 Inhibitors of cyclin-dependent kinases, compositions and uses related thereto

Publications (1)

Publication Number Publication Date
BRPI0418095A true BRPI0418095A (pt) 2007-04-17

Family

ID=34743691

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0418095-0A BRPI0418095A (pt) 2003-12-23 2004-12-21 inibidores de quinases dependentes de ciclina, composições e usos relacionados aos mesmos

Country Status (13)

Country Link
US (1) US8097619B2 (pt)
EP (1) EP1709051A1 (pt)
JP (1) JP4791975B2 (pt)
KR (1) KR101155883B1 (pt)
AU (1) AU2004309415B2 (pt)
BR (1) BRPI0418095A (pt)
CA (1) CA2551640C (pt)
EA (1) EA013117B1 (pt)
HK (1) HK1101399A1 (pt)
IL (1) IL176543A0 (pt)
MX (1) MXPA06007399A (pt)
NO (1) NO20063186L (pt)
WO (1) WO2005063765A1 (pt)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013075199A1 (pt) 2011-11-25 2013-05-30 Universidade Federal De Santa Catarina "compostos acil-hidrazonas e oxadiazóis, composições farmacêuticas compreendendo os mesmos e seus usos

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2584493A1 (en) * 2004-06-18 2006-01-05 Gpc Biotech, Inc. Kinase inhibitors for treating cancers
EP2019101A1 (en) 2007-07-26 2009-01-28 GPC Biotech AG Pyrazol[3,4-d]pyrimidin-4-one useful as Kinase Inhibitor
US8822447B2 (en) 2010-04-22 2014-09-02 Janssen Pharmaceutica Nv Indazole compounds useful as ketohexokinase inhibitors
EP3548488A1 (en) 2016-11-30 2019-10-09 Oncotyrol Center for Personalized Cancer Medicine GmbH 3-amino-1,5-dihydro-pyrazolo[3,4-d]pyrimidin-4-ones as cyclin dependent kinase inhibitors

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3211732A (en) 1965-10-12 Pyrazolob:x-d]pyrlil/hdines
CH398626A (de) 1960-05-11 1966-03-15 Ciba Geigy Verfahren zur Herstellung neuer Pyrazolopyrimidine
JPS60130521A (ja) 1983-12-19 1985-07-12 Morishita Seiyaku Kk 抗癌剤
US4678499A (en) 1985-03-11 1987-07-07 E. I. Du Pont De Nemours And Company Herbicidal sulfonamides
JPS6299361A (ja) 1985-10-25 1987-05-08 Morishita Seiyaku Kk インデノ〔１，２−ｃ〕ピラゾ−ル誘導体
TW444018B (en) 1992-12-17 2001-07-01 Pfizer Pyrazolopyrimidines
US5593997A (en) 1995-05-23 1997-01-14 Pfizer Inc. 4-aminopyrazolo(3-,4-D)pyrimidine and 4-aminopyrazolo-(3,4-D)pyridine tyrosine kinase inhibitors
US5866702A (en) 1996-08-02 1999-02-02 Cv Therapeutics, Incorporation Purine inhibitors of cyclin dependent kinase 2
US6407103B2 (en) * 1998-04-21 2002-06-18 Bristol-Myers Squibb Pharma Company Indeno [1,2-c] pyrazol-4-ones and their uses
CN1297442A (zh) 1998-04-21 2001-05-30 杜邦药品公司 用作抗癌剂和抗增殖剂的5－氨基茚并[1,2－c]吡唑－4－酮类化合物
US6531477B1 (en) 1998-10-13 2003-03-11 Dupont Pharmaceuticals Company 6-substituted pyrazolo [3,4-d] pyrimidin-4-ones useful as cyclin dependent kinase inhibitors
US6559152B2 (en) 1998-10-13 2003-05-06 Dupont Pharmaceuticals Company 6-substituted pyrazolo[3,4-d]pyrimidin-4-ones useful as cyclin dependent kinase inhibitors
US6291504B1 (en) 1999-10-20 2001-09-18 Dupont Pharmaceuticals Company Acylsemicarbazides and their uses
JP2004524277A (ja) 2000-10-20 2004-08-12 ブリストル−マイヤーズ スクイブ ファーマ カンパニー アシルセミカルバジド及びサイクリン依存性キナーゼ（ｃｄｋ）阻害剤としてのその使用
US6491971B2 (en) 2000-11-15 2002-12-10 G.T. Equipment Technologies, Inc Release coating system for crucibles
US6706718B2 (en) 2000-12-01 2004-03-16 Bristol-Myers Squibb Company 3-(2,4-dimethylthiazol-5-yl)indeno[1,2-c]pyrazol-4-one derivatives and their uses
CA2439263C (en) 2001-03-02 2012-10-23 Frank Becker Three hybrid assay system
US7605175B2 (en) * 2001-03-02 2009-10-20 Gpc Biotech Ag Inhibitors of cyclin-dependent kinases, compositions and uses related thereto
EP1404670A4 (en) 2001-07-06 2004-11-24 Bristol Myers Squibb Pharma Co SEMICARBAZIDES AND THEIR USE
US20040248905A1 (en) 2001-07-10 2004-12-09 Markwalder Jay A 6-Substituted pyrazolo [3,4-d] pyrimidin-4-ones useful as cyclin dependent kinase inhibitors
PL369742A1 (en) * 2001-10-15 2005-05-02 Gpc Biotech Inc. Inhibitors of cyclin-dependent kinases, compositions and uses related thereto
US6753329B2 (en) 2001-12-03 2004-06-22 Gpc Biotech Inc. Inhibitors of cyclin-dependent kinases, compositions and uses related thereto

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013075199A1 (pt) 2011-11-25 2013-05-30 Universidade Federal De Santa Catarina "compostos acil-hidrazonas e oxadiazóis, composições farmacêuticas compreendendo os mesmos e seus usos

Also Published As

Publication number Publication date
US8097619B2 (en) 2012-01-17
HK1101399A1 (en) 2007-10-18
KR20060130624A (ko) 2006-12-19
AU2004309415A1 (en) 2005-07-14
CA2551640A1 (en) 2005-07-14
NO20063186L (no) 2006-09-20
US20090209530A1 (en) 2009-08-20
AU2004309415B2 (en) 2010-08-26
JP2007516296A (ja) 2007-06-21
WO2005063765A1 (en) 2005-07-14
JP4791975B2 (ja) 2011-10-12
EA200601216A1 (ru) 2006-12-29
KR101155883B1 (ko) 2012-06-20
MXPA06007399A (es) 2007-01-26
CA2551640C (en) 2012-09-11
EP1709051A1 (en) 2006-10-11
EA013117B1 (ru) 2010-02-26
IL176543A0 (en) 2006-10-05

Similar Documents

Publication Publication Date Title
BRPI0417708A (pt) derivados organofosfóricos dos indazóis e sua utilização como inibidores das proteìnas quinases
BR112022002581A2 (pt) Inibidores heterocíclicos de rip1 quinase
YU49101A (sh) Karboksiaril supstituisani difenil karbamidi kao inhibitori raf kinaze
BRPI0312464B8 (pt) compostos inibidores de tirosina quinases, composições farmacêuticas compreendendo os mesmos, processos para fabricação e usos dos mesmos
MX2022001940A (es) Compuestos de imidazolil pirimidinilamina como inhibidores de cdk2.
AR024138A1 (es) Inhibidores de la proliferacion celular
BRPI0514125A (pt) piridinas condensadas como inibidores de cinase
MY133159A (en) Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases
BRPI0514371A (pt) 2, 4 di (aminofenil) pirimidina como inibidores de plk
ECSP088283A (es) Compuestos de piridina 5- (fenilisoxazoliletoxi) -triazol- 3-ilo substituidos para el tratamiento de trastornos neurológicos, psiquiátricos o del dolor
BRPI0821743B8 (pt) derivados de piridazinona, e seu uso
BRPI0616987A2 (pt) pirazolopirimidinas como inibidores de cinase dependente de ciclina
BR0316296A (pt) Compostos lapacone e seus métodos de uso
BRPI0606675A2 (pt) agonista receptor de neuropeptìdio-2, composições farmacêuticas que compreendem o mesmo, compostos, método para o tratamento terapêutico e/ou profilático de enfermidades e utilização dos compostos
BRPI0418031A (pt) inibidores de quinase fosfonato-substituìdos
TR200003514T2 (tr) Pirol ikame edilmiş 2-indolinon protein kinaz inhibitörleri
BR112022019492A2 (pt) Inibidores de rip1k
BR9911482A (pt) Composto, composição farmacêutica, uso do composto, e, processos para o tratamento ou profilaxia de doenças inflamatórias, e para a preparação de um composto
AR029383A1 (es) Moleculas pequenas, los intermediarios para su sintesis, las composiciones farmaceuticas que las contienen y su uso para preparar un medicamento destinado al tratamiento o la profilaxis de enfermedades inflamatorias o mediadas por celulas inmunes
BR0111206A (pt) Derivados de arilmetilamina para uso como inibidores de triptase
ATE230394T1 (de) Indolderivate und deren verwendung zur behandlung von malignen und anderen, auf pathologischen zellproliferationen beruhenden erkrankungen
ECSP034924A (es) Derivados sustituidos del 1-oxa-2,8-daza-espiro[4,5]dec-2-eno
ECSP078062A (es) Heterociclos de 1,4-dihidropiridina-condensados, procesos para preparar los mismos, uso y composiciones que los contienen
BR0212856A (pt) Compostos de benzimidazol substuìdos e seu uso para o tratamento do câncer
BR0315662A (pt) Derivados de 1-(4-benzil-piperazin-1-il)-3-fenil-propenona

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25D Requested change of name of applicant approved

Owner name: AGENNIX USA INC. (US)

Free format text: NOME ALTERADO DE: GPC BIOTECH, INC.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 9A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2260 DE 29/04/2014.